[{"id":"33062010-2f9f-457a-bb48-293b21b77b51","acronym":"RAGNAR","url":"https://clinicaltrials.gov/study/NCT04083976","created_at":"2021-01-18T19:59:45.508Z","updated_at":"2025-02-25T12:37:25.290Z","phase":"Phase 2","brief_title":"A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations","source_id_and_acronym":"NCT04083976 - RAGNAR","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR2 • FGFR • TACC3 • TACC2","pipe":" | ","alterations":" FGFR3 mutation • FGFR mutation • FGFR fusion","tags":["FGFR2 • FGFR • TACC3 • TACC2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR3 mutation • FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 316","initiation":"Initiation: 11/20/2019","start_date":" 11/20/2019","primary_txt":" Primary completion: 12/04/2023","primary_completion_date":" 12/04/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-24"},{"id":"9480eee5-c88d-4aa5-a04a-bfe171590b90","acronym":"INCB 84344-102","url":"https://clinicaltrials.gov/study/NCT03934372","created_at":"2021-01-18T19:22:38.750Z","updated_at":"2025-02-25T14:40:12.243Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","source_id_and_acronym":"NCT03934372 - INCB 84344-102","lead_sponsor":"Incyte Biosciences International Sàrl","biomarkers":" FLT3 • ABL1 • BCR • RET • FGFR • BLM","pipe":" | ","alterations":" EGFR mutation • KIT mutation • FGFR mutation • RET mutation","tags":["FLT3 • ABL1 • BCR • RET • FGFR • BLM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • KIT mutation • FGFR mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/29/2020","start_date":" 01/29/2020","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-14"},{"id":"ab21b4e4-b3ac-475c-9005-48c011e2a7c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05316155","created_at":"2022-04-07T12:57:01.192Z","updated_at":"2025-02-25T15:27:19.690Z","phase":"Phase 1/2","brief_title":"Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer","source_id_and_acronym":"NCT05316155","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Balversa (erdafitinib) • erdafitinib intravesical delivery system (TAR-210)"],"overall_status":"Recruiting","enrollment":" Enrollment 262","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 03/30/2028","primary_completion_date":" 03/30/2028","study_txt":" Completion: 09/19/2029","study_completion_date":" 09/19/2029","last_update_posted":"2025-02-10"},{"id":"25d363db-b73d-42b4-a08a-717568224b15","acronym":"THOR-2","url":"https://clinicaltrials.gov/study/NCT04172675","created_at":"2021-01-18T20:21:16.432Z","updated_at":"2025-02-25T17:00:18.386Z","phase":"Phase 2","brief_title":"A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)","source_id_and_acronym":"NCT04172675 - THOR-2","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Balversa (erdafitinib) • mitomycin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 02/28/2020","start_date":" 02/28/2020","primary_txt":" Primary completion: 07/12/2024","primary_completion_date":" 07/12/2024","study_txt":" Completion: 03/03/2025","study_completion_date":" 03/03/2025","last_update_posted":"2025-02-03"},{"id":"7bb8b08e-5d1b-431b-b5ae-8689cf85f453","acronym":"","url":"https://clinicaltrials.gov/study/NCT05656235","created_at":"2024-01-16T22:19:54.900Z","updated_at":"2025-02-25T15:36:00.703Z","phase":"Phase 2","brief_title":"Renal Retention in High Grade Upper Tract Urothelial Cancer","source_id_and_acronym":"NCT05656235","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/25/2024","start_date":" 11/25/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-12-11"},{"id":"43f66187-5b30-4357-8f5c-84f785cedc80","acronym":"POD1UM-204","url":"https://clinicaltrials.gov/study/NCT04463771","created_at":"2021-01-18T21:27:26.857Z","updated_at":"2024-07-02T16:34:37.736Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.","source_id_and_acronym":"NCT04463771 - POD1UM-204","lead_sponsor":"Incyte Corporation","biomarkers":" PD-L1 • MSI • POLE","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • FGFR mutation • FGFR1 mutation","tags":["PD-L1 • MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • FGFR mutation • FGFR1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib) • Zynyz (retifanlimab-dlwr) • epacadostat (INCB024360) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-06-06"},{"id":"0b4bc025-bfab-4d27-a83b-163254f008e0","acronym":"CR109248","url":"https://clinicaltrials.gov/study/NCT05567185","created_at":"2022-10-05T13:56:18.093Z","updated_at":"2024-07-02T16:35:02.053Z","phase":"Phase 1","brief_title":"A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer","source_id_and_acronym":"NCT05567185 - CR109248","lead_sponsor":"Janssen Pharmaceutical K.K.","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erdafitinib intravesical delivery system (TAR-210)"],"overall_status":"Recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 03/03/2023","start_date":" 03/03/2023","primary_txt":" Primary completion: 10/16/2026","primary_completion_date":" 10/16/2026","study_txt":" Completion: 09/24/2027","study_completion_date":" 09/24/2027","last_update_posted":"2024-05-22"},{"id":"e391f2a5-896d-4821-b066-fdd97cba862d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04919642","created_at":"2021-06-10T01:52:34.634Z","updated_at":"2024-07-02T16:35:07.347Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma","source_id_and_acronym":"NCT04919642","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tinengotinib (TT-00420)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 02/28/2024","study_completion_date":" 02/28/2024","last_update_posted":"2024-04-26"},{"id":"07a51dc9-114c-48cd-acba-f59680179bb5","acronym":"INNATE","url":"https://clinicaltrials.gov/study/NCT04669899","created_at":"2021-07-23T15:52:37.047Z","updated_at":"2024-07-02T16:35:10.864Z","phase":"Phase 1/2","brief_title":"Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT04669899 - INNATE","lead_sponsor":"Jounce Therapeutics, Inc.","biomarkers":" EGFR • PD-L1 • ALK • IDH1 • FGFR","pipe":" | ","alterations":" EGFR mutation • IDH1 mutation • ALK rearrangement • FGFR mutation","tags":["EGFR • PD-L1 • ALK • IDH1 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • IDH1 mutation • ALK rearrangement • FGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pimivalimab (JTX-4014) • polzastobart (JTX-8064)"],"overall_status":"Completed","enrollment":" Enrollment 190","initiation":"Initiation: 01/12/2021","start_date":" 01/12/2021","primary_txt":" Primary completion: 11/28/2023","primary_completion_date":" 11/28/2023","study_txt":" Completion: 11/28/2023","study_completion_date":" 11/28/2023","last_update_posted":"2024-04-09"},{"id":"2354d741-07d7-4fa3-9724-54f92f01122f","acronym":"FORTUNE","url":"https://clinicaltrials.gov/study/NCT04962867","created_at":"2021-07-15T13:06:08.522Z","updated_at":"2025-02-25T13:35:52.987Z","phase":"Phase 2","brief_title":"NCCH2006/MK010 Trial (FORTUNE Trial)","source_id_and_acronym":"NCT04962867 - FORTUNE","lead_sponsor":"National Cancer Center, Japan","biomarkers":" EGFR • KRAS • BRAF • ALK • NRAS • FGFR2 • ROS1 • FGFR4 • NTRK","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR2 mutation • FGFR2 fusion • FGFR mutation","tags":["EGFR • KRAS • BRAF • ALK • NRAS • FGFR2 • ROS1 • FGFR4 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR2 mutation • FGFR2 fusion • FGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tasfygo (tasurgratinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 06/15/2021","start_date":" 06/15/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-01-08"},{"id":"fc5e8b29-6dcb-4531-a767-ace8038c4ef9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02272998","created_at":"2021-01-18T10:41:33.356Z","updated_at":"2024-07-02T16:35:36.656Z","phase":"Phase 2","brief_title":"Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.","source_id_and_acronym":"NCT02272998","lead_sponsor":"Sameek Roychowdhury","biomarkers":" FLT3 • ABL1 • RET • PDGFRA • FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FLT3 • ABL1 • RET • PDGFRA • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 02/24/2015","start_date":" 02/24/2015","primary_txt":" Primary completion: 11/17/2022","primary_completion_date":" 11/17/2022","study_txt":" Completion: 11/17/2023","study_completion_date":" 11/17/2023","last_update_posted":"2023-09-18"},{"id":"ebd5d4f3-9c51-4862-880f-738277ea8dc8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05216120","created_at":"2022-02-05T18:27:56.347Z","updated_at":"2024-07-02T16:35:44.081Z","phase":"Phase 2","brief_title":"Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas","source_id_and_acronym":"NCT05216120","lead_sponsor":"HonorHealth Research Institute","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation • FGFR fusion","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation • FGFR fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2023-07-03"},{"id":"c7ffedfa-b221-47a0-8188-045db5ae4afc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02691793","created_at":"2021-01-18T13:07:48.373Z","updated_at":"2024-07-02T16:36:08.891Z","phase":"Phase 4","brief_title":"Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors","source_id_and_acronym":"NCT02691793","lead_sponsor":"Samsung Medical Center","biomarkers":" RET • FGFR2","pipe":" | ","alterations":" RET fusion • FGFR2 mutation • FGFR2 fusion • FGFR mutation • RET positive","tags":["RET • FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • FGFR2 mutation • FGFR2 fusion • FGFR mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib"],"overall_status":"Completed","enrollment":" Enrollment 1","initiation":"Initiation: 11/20/2017","start_date":" 11/20/2017","primary_txt":" Primary completion: 08/30/2019","primary_completion_date":" 08/30/2019","study_txt":" Completion: 11/19/2019","study_completion_date":" 11/19/2019","last_update_posted":"2022-06-15"},{"id":"b2085133-26bf-4375-9531-ece717adb23a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04339933","created_at":"2021-01-18T21:00:23.823Z","updated_at":"2024-07-02T16:36:13.493Z","phase":"","brief_title":"Detection of FGFR Gene Mutations in the Tumor Tissue and Urine of Patients With Urothelial Carcinoma","source_id_and_acronym":"NCT04339933","lead_sponsor":"Ho Kyung Seo","biomarkers":" PD-L1 • FGFR","pipe":" | ","alterations":" PD-L1 expression • FGFR mutation","tags":["PD-L1 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • FGFR mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2022-04-07"},{"id":"f45473e2-7a95-4d17-95ba-c86a27ceffbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT01244438","created_at":"2021-01-18T05:00:42.606Z","updated_at":"2024-07-02T16:36:19.600Z","phase":"Phase 2","brief_title":"Study of FP-1039 in Subjects With Endometrial Cancers","source_id_and_acronym":"NCT01244438","lead_sponsor":"Five Prime Therapeutics, Inc.","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 mutation • FGFR mutation • FGFR2 S252W","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR mutation • FGFR2 S252W"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FP-1039"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 06/01/2012","primary_completion_date":" 06/01/2012","study_txt":" Completion: 12/01/2012","study_completion_date":" 12/01/2012","last_update_posted":"2021-12-13"},{"id":"e9fbe660-e738-46c7-9c2a-9818bd84d26c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04936295","created_at":"2021-06-23T17:52:35.212Z","updated_at":"2024-07-02T16:36:28.767Z","phase":"Phase 2","brief_title":"Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation","source_id_and_acronym":"NCT04936295","lead_sponsor":"Sun Yat-sen University","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative • FGFR1 amplification • FGFR mutation","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • FGFR1 amplification • FGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib) • fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 06/16/2021","start_date":" 06/16/2021","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2021-06-23"},{"id":"75de18f5-155e-45d7-85e4-d37abf65ca4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT01976741","created_at":"2021-03-02T12:23:56.095Z","updated_at":"2025-02-25T17:07:13.668Z","phase":"Phase 1","brief_title":"Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)","source_id_and_acronym":"NCT01976741","lead_sponsor":"Bayer","biomarkers":" FGF23","pipe":" | ","alterations":" FGFR mutation","tags":["FGF23"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rogaratinib (BAY 1163877)"],"overall_status":"Completed","enrollment":" Enrollment 168","initiation":"Initiation: 12/30/2013","start_date":" 12/30/2013","primary_txt":" Primary completion: 03/11/2019","primary_completion_date":" 03/11/2019","study_txt":" Completion: 01/09/2020","study_completion_date":" 01/09/2020","last_update_posted":"2021-05-06"},{"id":"ce4b4f56-c5da-4d43-b000-8a1109016e62","acronym":"","url":"https://clinicaltrials.gov/study/NCT03929965","created_at":"2021-01-18T19:21:41.718Z","updated_at":"2024-07-02T16:37:00.115Z","phase":"","brief_title":"Anlotinib in Advanced Solid Tumors With FGFR Alteration","source_id_and_acronym":"NCT03929965","lead_sponsor":"Shanghai Changzheng Hospital","biomarkers":" FGFR","pipe":" | ","alterations":" FGFR mutation","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Focus V (anlotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2019","start_date":" 07/01/2019","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 07/01/2023","study_completion_date":" 07/01/2023","last_update_posted":"2019-04-29"}]